Plaintiffs Lack Standing In Flonase Suit: GSK

Law360, New York (October 20, 2008, 12:00 AM EDT) -- GlaxoSmithKline PLC says that plaintiffs who brought an indirect purchasers action alleging the company stalled the approval of a generic version of Flonase don't have standing because they failed to state a cause of action under state antitrust and consumer protection laws.

In a motion filed Friday in the U.S. District Court for the Eastern District of Pennsylvania, the drugmaker asked the court to dismiss the amended class action, alleging that the plaintiffs are doing an end-run around a U.S. Supreme Court decision that would block...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.